Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 22,018 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Bereavement, Suicide
Interventions: WELL Behavioral Probe; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 158
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more

Conditions: Multiple Myeloma
Interventions: AZD0305, Dexamethasone, Elranatamab, Pomalidomide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Duarte, California • Irvine, California • Atlanta, Georgia + 6 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Placebo (sucrose), Roseomonas mucosa (RSM2015) and Cardamom seeds; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Familial Platelet Disorder With Predisposition to Myeloid Malignancies, Inherited Bone Marrow Failure Syndrome
Interventions: TruSight Oncology, imatinib; Device · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer Pain, Cancer of Breast, Depressive Symptoms
Interventions: CAI, CAPA; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: EGFR/HER2 Exon 20 Insertion Mutation, NSCLC, Non-Small Cell Lung Cancer
Interventions: STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (Escalated), STX-721/PFL-721 (Escalated) with platinum-based chemotherapy, STX-721/PFL-721 (RP2D), STX-721/PFL-721 with platinum-based chemotherapy; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 6 more

Conditions: Acute Myelogenous Leukemia, Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer
Interventions: Web based survey; Other
Lead sponsor: Carevive Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: New Haven, Connecticut • Evanston, Illinois • Chapel Hill, North Carolina + 4 more

Conditions: Hemorrhage, Trauma
Interventions: Calcium Gluconate, Vasopressin, saline placebo; Drug
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Acalabrutinib, Rituximab; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 65 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: Berkeley, California • La Jolla, California • Orange, California + 11 more

Conditions: Amyotrophic Lateral Sclerosis (ALS), BCI, Brain-computer Interface, Brainstem Stroke, Cervical Spinal Cord Injury, Paralysis, Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury
Interventions: Mind Extender (MindEx); Device
Lead sponsor: Nader Pouratian; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Kidney Disease
Interventions: Exercise Training, Placebo, Sodium Bicarbonate; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Cortical Blindness, Unspecified Side of Brain, Hemianopia, Homonymous
Interventions: Multisensory Training, Unisensory Training; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bile Duct Cancer, Biliary Cancer, Cancer of the Bile Duct
Interventions: CDX-1140, Keytruda, capecitabine, oxaliplatin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 180 Days to 22 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 108
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more

Conditions: Tachycardia, Ventricular
Interventions: Catheter Ablation (CA), Varian Cardiac Radioablation (CRA); Procedure · Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 12
States / cities: Los Angeles, California • Hartford, Connecticut • New Haven, Connecticut + 9 more

Conditions: Invasive Candidiasis
Interventions: therapy duration; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 120 Days and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 21
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more

Conditions: Localized Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Cancer
Interventions: Exercise Therapy; Behavioral
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Hartford, Connecticut + 7 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Digital Photography, Lumbar Puncture, Magnetic Resonance Imaging, Medical Device Usage and Evaluation; Procedure · Other · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Autism Spectrum Disorder
Interventions: Sham, trans cranial direct current stimulation (tDCS); Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 5 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Dalls, Texas

Conditions: Solid Tumor
Interventions: Indocyanine Green; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 20 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Memphis, Tennessee

Conditions: Viral Lung Infection and Acute Respiratory Failure
Interventions: Placebo, Tozorakimab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: ASCVD, Bone Marrow Transplant Complications, Cisplatin Adverse Reaction, Coronary Artery Disease, Hypogonadism, Male, Lipid Disorder, Survivorship, Testicular Cancer
Interventions: Coronary artery assessment, Hormone levels for hypogonadism, Lipid profile; Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, Pomalidomide, mezigdomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 56
States / cities: Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more

Search by objective public record fields.

Risk and Resilience to Suicide Following Late-Life Spousal Bereavement

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Cardamom and Topical Roseomonas in Atopic Dermatitis

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Cancer Pain Management Using a Web-based Intervention

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

Ameliorating Stroke-induced Hemianopia Via Multisensory Training

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Cerebellar Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder: Raynor Cerebellum Project

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)